IBIO Stock Risk & Deep Value Analysis
iBio Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on IBIO
We analyzed iBio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IBIO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈IBIO Performance Overview3yr weekly
Unlock IBIO Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
IBIO Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
About iBio Inc (IBIO)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$40.13M
IBIO Deep Value Analysis
IBIO Red Flags & Warning Signs
Premium- ⚠
Negative or inconclusive Phase 1 clinical trial results
- ⚠
Further equity dilution to fund operations
- ⚠
Failure to secure additional funding or partnerships
- ⚠
Competitive advancements in plant-based expression or target indications
Unlock IBIO Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
IBIO Financial Health Metrics
Market Cap
$40.13M
IBIO Competitive Moat Analysis
PremiumMoat Rating
None
Moat Trend
Stable
Moat Sources
1 Identified
The FastPharming technology represents a potential competitive advantage, but its durability as a true moat is unproven. It depends heavily on successful clinical validation, demonstrating clear advantages over traditional mammalian cell culture or microbial systems, and securing robust patent protection that withstands challenges. Without successful commercialization and differentiation, it remains a promising technology rather than a durable moat.
IBIO Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
IBIO Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Preclinical data updates for lead candidates (IBIO-101, IBIO-200 series)
Medium-Term (6-18 months)
- •Initial Phase 1 clinical trial data readout for lead oncology candidate (IBIO-101)
- •Potential strategic partnership or collaboration announcement for FastPharming platform or specific programs
Long-Term (18+ months)
- •Advancement of lead candidates into Phase 2 clinical trials
- •Broader adoption and validation of FastPharming technology across multiple therapeutic areas
- •Successful commercialization of a novel plant-based therapeutic
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
IBIO Bull Case: What Could Go Right
- ✓
Positive Phase 1 clinical trial data for IBIO-101 (efficacy, safety, tolerability)
- ✓
New strategic partnerships or significant non-dilutive funding rounds
- ✓
Reduction in quarterly cash burn without compromising R&D
Bull Case Analysis
See what could go right with Premium
Never miss a move on IBIO
Create a free account to set price alerts and get notified on Telegram when IBIO hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for iBio Inc (IBIO)?
As of March 1, 2026, iBio Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of iBio Inc?
iBio Inc's market capitalization is approximately $40.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does iBio Inc use?
IBIO is the ticker symbol for iBio Inc. The company trades on the NCM.
What is the risk level for IBIO stock?
Our analysis rates iBio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the IBIO DVR analysis updated?
Our AI-powered analysis of iBio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.